New 'Super' cell therapy tested for tough liver cancers
NCT ID NCT07493044
Summary
This is an early-stage safety study testing a new type of personalized cell therapy for patients with advanced liver cancer. The therapy, called 'Super CAR-T,' involves modifying a patient's own immune cells to target a specific protein (GPC3) found on their cancer cells. The main goal is to find a safe dose for this experimental treatment in a small group of patients who have already tried and failed at least two standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Gaungdong, 510700, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.